PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • Accomplished Biophysicist Linnéa Olofsson, Ph.D. joins PreveCeutical

    Vancouver, British Columbia--(Newsfile Corp. - February 23, 2021) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is very pleased to announce the appointment of Dr. Linnéa Olofsson as an advisor and consultant for the Company.Dr. Olofsson will be working with our team in implementing our strategies for the commercialization of our products. With her scientific background and ability to understand the needs in the medical field, she will be collaborating to bring important solutions to...

    2021-02-23 8:00 AM ET
  • PreveCeutical Announces Completion of Pain Management Peptides Program

    Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) -  PreveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)  (the "Company" or "PreveCeutical") is pleased to announce the successful completion of its non-addictive analgesic program ("Analgesic Program").The Analgesic Program started in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation. The Company has received the final research project report from UniQuest Pty Ltd. for this discovery program, which utilized a proprietary disulfide linker technology.Further to the...

    2021-02-02 8:00 AM ET
  • PreveCeutical files Provisional Patent Application for its BSV Peptide

    Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on December 22, 2020, entitled "Cyclic Peptides and Uses Thereof", application number 2020904798, with the aim of seeking protection for certain cyclic peptides and their use in prevention and treatment of brain cancer.Peptides derived from the Blue Scorpion Venom ("BSV") have shown promise in...

    2021-01-05 8:00 AM ET
  • Successful Completion of the COVID-19 Sol-Gel Formulation Development

    Vancouver, British Columbia--(Newsfile Corp. - November 25, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce the successful laboratory development of a cannabinoid Sol-Gel formulation ("SARS-CoV-2 Sol-Gel") as a potential prevention/treatment for COVID-19 caused by SARS-CoV-2 infection.Independent scientific literature has reported that high CBD strains could potentially have beneficial properties for the prevention/treatment of SARS-CoV-2 infection. (peer-reviewed hypothesis paper titled "The potential of cannabidiol in the COVID-19 pandemic", dated May 29, 2020, published in...

    2020-11-25 8:00 AM ET
  • PreveCeutical Files Provisional Patent Application for its COVID-19 Formulation

    Vancouver, British Columbia--(Newsfile Corp. - November 23, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 20, 2020, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use", application number 20200904291, with the aim of seeking protection for certain cannabinoid formulations and their use in prevention and treatment of COVID-19 caused by SARS-CoV-2 infection.PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented,...

    2020-11-23 7:30 AM ET
  • PreveCeutical Provides Update on Its COVID-19 Cannabinoid Sol-Gel Program

    Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to provide an update on its COVID-19 Cannabinoid Sol-Gel Program ("COVID-19 CBD Program") (see news release dated May 4, 2020).With the successful completion of the COVID-19 CBD Program, a sol-gel based formulation has been developed to deliver medicinal cannabis. The Company will provide further information once the final report for this program is received.The Company is not making any express...

    2020-11-10 7:00 AM ET
  • PreveCeutical Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia

    Vancouver, British Columbia--(Newsfile Corp. - October 29, 2020) -  PreveCeutical Medical Inc.  (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has been granted an extension of six months by the Registrar of Companies, to hold its Annual General Meeting ("AGM")for the year 2020 under section 182(4) of the Business Corporations Act. The six months extension is from October 29, 2020, to April 29, 2021.With the challenges related to COVID-19, the Company's management determined that...

    2020-10-29 2:38 PM ET
  • PreveCeutical's Application for COVID-19 Therapy Funding Update

    Vancouver, British Columbia--(Newsfile Corp. - October 9, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") informs that in reference to its current work to develop medical countermeasures in response to COVID-19 (News Release dated May 4, 2020), PreveCeutical has received notification from the Strategic Innovation Fund ("SIF") that its proposal, which was part of the second phase of Canada's National Medical Research Strategy in response to COVID-19, will not be receiving further consideration under this program....

    2020-10-09 3:15 PM ET